Logo image
Back
Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription
Journal article   Open access   Peer reviewed

Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription

Rebecca Kaufman, Guillermo Flores, Elissa A Boguslawski, Seneca Kinn-Gurzo, Maggie Chassé, Ian Beddows, Marie Adams, Matthew C Stout, Lauren Gaetano, Raphael Lopez, …
Nature communications, Vol.17(1), 2844
02/16/2026
DOI: 10.1038/s41467-026-69488-9
PMCID: PMC13021929
PMID: 41698909
url
https://doi.org/10.1038/s41467-026-69488-9View
Published (Version of record) Open Access

Abstract

Although many DNA binding natural products exert their effects through non-specific mechanisms, a therapeutic opportunity exists for a subset of these compounds that alter the expression or activity of specific driver oncogenes in specific cell contexts. In this study, we integrate CUT&Tag with Global Run-On Sequencing (CUT, Tag, and GRO) to show that the minor groove binding compound, mithramycin (MMA), inhibits the Ewing sarcoma oncogenic driver, the EWS::FLI1 transcription factor. MMA causes either an increase or decrease in EWS::FLI1 binding to chromatin at downstream target response elements to poison nascent transcription. The reversal of EWS::FLI1 activity is limited by non-specific effects of the drug on RNAPII processivity but can be optimized by continuous administration at low concentration to cause more precise reversal of the oncogenic transcriptome and striking Ewing sarcoma xenograft regressions. The activity in vivo is further improved with a less-toxic second-generation analog, AIT-102.

Details

Metrics

1 Record Views
Logo image